13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • Exelixis

    Acronym: 

    COSMIC-313

    ACTRN/NCT /ethics: 

    NCT03937219

    Scientific title: 

    Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

    Summary of trial and patient characteristics

    Cancer Type Kidney
    Trial Type Treatment
    Phase Phase III Tumour Stream Renal cell carcinoma
    Age Range 18 years and older Cancer Stage
    Sex Both Anticipated Start Date 2019-08-01
    Molecular Target Anticipated End Date 2024-06-01
    Cancer Type Kidney
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Renal cell carcinoma
    Cancer Stage
    Anticipated Start Date 2019-08-01
    Anticipated End Date 2024-06-01

    Trial Summary

    A randomised, double-blind, controlled phase III study of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in previously untreated advanced or metastatic renal cell carcinoma of intermediate or poor risk

    Lay Summary

    Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

    Sponsor / Cooperative group

    Exelixis

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Calvary North Adelaide Hospital Julie Rowe julie.rowe@calvarycare.org.au 08 8239 9536 Recruiting